GSE192536
Boosting NAD+ blunts toll-like receptor-4 induced type I interferon in control and systemic lupus erythematosus monocytes
This is a pilot study to evaluate the effects of NR supplementation on monocytes function, registered in ClinicalTrials.gov with registration number: NCT02812238 and approved by the National Heart and Lung Institute IRB. Overall design: Healthy volunteers were screened prior to signing consent and subjects were then randomly assigned to a 7-day supplementation of either NR (1000 mg daily) or a matching placebo. After one week of therapy, subjects underwent a 24-hour fast followed by an early-morning fixed 500-calorie meal. Blood draw was taken before and 3hrs. after feeding